OPTIMA

Prof James C Spratt has global experience in training physicians in complex and CTO PCI. He is the Director of Optimal CTO and the author of the Retrograde iBook and co-author of the antegrade iBook.

Dr Simon Walsh has been working as a Consultant Cardiologist at the Belfast Trust for over 10 years. It is one of the largest NHS trusts in the UK. The centre performs ~2750 PCI per year, with 650-700 STEMI and calcium modification in ~10% of our PCI cases. Dr Walsh also works internationally as an educator, teaching advanced techniques for complex PCI and CTO PCI. This involves training visiting Cardiologists in Belfast retrograde CTO techniques, antegrade dissection and re-entry CTO techniques and other advanced PCI procedures. He has visited multiple centres in the UK, Ireland, Europe, Australia, Asia and North America to act as a visiting proctor for complex PCI and CTO PCI cases. Dr Walsh’s research interests include PCI, coronary artery disease, defibrillation, acute coronary syndromes and chronic total occlusions. Research responsibilities have included acting as a recruiting investigator for the >25 multicentre studies over the last 17 years. He acted as a primary investigator for numerous international trials including the Evolve, Noble, Leaders Free and Ischemia multicentre studies. He has been the lead UK investigator for the October trial, Syntax 2, Recharge and Ischaemia-CTO. He is also the Chief Investigator for the Consistent CTO, Celtic Bifurcation and Discrete CTO trials.

A consultant cardiologist at Mater Private Hospital, Dublin, Ireland. Features in 20 videos on Wondr Medical. Colm Hanratty generally speaks on Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Chronic Total Occlusion (CTO), Calcium Scoring, and Stable Coronary Artery Disease (CAD).

Dr Julian Strange is a consultant interventional cardiologist at Bristol Heart Institute, UK. His specialty and research interests are in coronary disease and include coronary angioplasty, complex PCI and chronic total occlusions (CTO) as well as advanced heart attack and cardiac arrest therapies.